Corvus Pharmaceuticals (Nasdaq: CRVS) announced the publication of peer-reviewed final data from its Phase 1/1b trial of soquelitinib in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE